Massive study tests PCV20 Vaccine's power against pneumonia
NCT ID NCT07251465
First seen Jan 05, 2026 · Last updated May 25, 2026 · Updated 27 times
Summary
This study checks how well the PCV20 vaccine prevents pneumonia and other lung infections in adults 18 and older who are at higher risk. Researchers will look at health records from over 800,000 people at Kaiser Permanente Southern California, comparing those who got the vaccine to those who did not. The goal is to see if the vaccine reduces pneumonia cases over a three-year period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.